Drugs / HRS-9057
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07681479 | Aug 2026 overdue | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06506994 | Aug 2024 → Oct 2025 | heart failure | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07318103 | Dec 2025 → Sep 2026 overdue | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-9057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06506994 ↗ |